InVivo Therapeutics Holdings Corporation (NVIV)
NVIVPrice: $0.32
Fair Value: 🔒
🔒score
InVivo Therapeutics Holdings Corp., a research and clinical-stage biomaterials and biotechnology company, engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries (SCI). It is developing a Neuro-Spinal Scaffold implant, which is an investigat... more
InVivo Therapeutics Holdings Corp., a research and clinical-stage biomaterials and biotechnology com... more
Description
Shares
| Market Cap | $995,918 | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | Richard M. Toselli |
| IPO Date | 2010-11-15 | CAGR | — |
| Employees | 6 | Website | www.invivotherapeutics.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
NVIV chart loading...
Fundamentals
Technicals
| Enterprise Value | $-5.10M | P/E Ratio | -0.1 |
| Forward P/E | — | PEG Ratio | — |
| P/S Ratio | — | P/B Ratio | 0.03 |
| P/CF Ratio | -0.05 | P/FCF Ratio | -0.09 |
| EPS | $-3.28 | EPS Growth 1Y | — |
| EPS Growth 3Y | — | EPS Growth 5Y | — |
| Revenue Growth 1Y | — | Gross Margin | — |
| Operating Margin | — | Profit Margin | — |
| ROE | -0.6% | ROA | -0.54% |
| ROCE | -0.65% | Current Ratio | 7.13 |
| Quick Ratio | 7.13 | Cash Ratio | 6.63 |
| Debt/Equity | 0.06 | Interest Coverage | -70.53 |
| Altman Z Score | -38.7 | Piotroski Score | 2 |
View InVivo Therapeutics Holdings Corporation financial charts →